The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc.

Friday, February 08, 2013

Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc.12:42 EST Friday, February 08, 2013NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Harwood Feffer LLP ( is investigating potential claims against the board of directors of Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX), concerning whether the board has breached its fiduciary duties to shareholders.(Logo: )On April 2, 2012, the Company disclosed that the Phase 3 Clinical Trial did not meet the primary endpoint of improving patient survival when compared to another drug and a placebo.  On this news, the Company's shares lost more than 60% of their value over two trading days.   Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing. If you own Keryx shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:Robert I. Harwood, Esq.  Matthew M. Houston, Esq.  Benjamin I. Sachs-Michaels, Esq.  Harwood Feffer LLP  488 Madison Avenue  New York, New York 10022  Phone Numbers: (877) 935-7400                           (212)935-7400Email: Website:   http://www.hfesq.comHarwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ( for more information about the firm.Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter.SOURCE Harwood Feffer LLP